Syncromune™
Danielle Hobbs has a diverse work experience in the healthcare industry. In their most recent role as EVP of Investor Relations & Corporate Communications at Syncromune™, a biopharmaceutical company, they are responsible for developing novel intratumoral immunotherapies for solid tumors. Prior to that, Danielle served as Co-Chair of the Emergency Medicine Advisory Board at Brigham and Women's Hospital.
In 2005, Danielle founded Medevixx, a boutique firm that focused on addressing the lack of training in the medical device industry. Danielle later became the President of the company.
Danielle also served as the Chief Operating Officer at Summa Therapeutics, where they played a crucial role in the development of advanced angioplasty technologies. Danielle was responsible for facilitating angioplasty procedures with fewer steps and less equipment, saving time and resources.
Before joining Summa Therapeutics, Danielle served as the VP of Marketing & Communications at ImmunSYS, Inc., where they played a crucial role in promoting the company's products and services.
Danielle has also co-founded Capture Vascular, an early-stage medical device company, and served as the CEO. The company focused on developing clot removal solutions in interventional vascular medicine.
Earlier in their career, Danielle worked at AngioDynamics, Inc. as an Interventional Sales Specialist and Corporate Sales Trainer. Danielle managed a large sales territory, developed relationships with key physicians, and facilitated physicians in surgical cases.
Danielle started their career as a Sales Trainer at Forest Laboratories, where they were responsible for training and developing new representatives. Danielle later became a Territory Manager and Field Sales Trainer, achieving outstanding sales performance.
Overall, Danielle Hobbs has a strong background in the healthcare industry, with experience in various roles such as executive leadership, sales, marketing, and training. Danielle has a proven track record in developing and commercializing medical devices, as well as building relationships with key stakeholders.
Danielle Hobbs has pursued their education at Ohio University, where they obtained a Bachelor of Science degree. Danielle'sfield of study involved Physiology and Pre-Med.
This person is not in any teams
This person is not in any offices
Syncromune™
1 followers
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringinglife-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.